PedAM
Pediatric Disease Annotations & Medicines
| Disease | multiple myeloma |
| Symptom | C0020437|hypercalcemia |
| Sentences | 8 |
| PubMedID- 25803181 | These findings in combination with the acute renal lesion at presentation and hypercalcemia confirmed the diagnosis of multiple myeloma-related systemic al amyloidosis. |
| PubMedID- 24334568 | It is the most common primary bone malignancy, and the extensive osteoclastic bone resorption common in multiple myeloma is associated with hypercalcemia in as many as one-third of patients. |
| PubMedID- 23700375 | After the diagnosis of multiple myeloma with hypercalcemia, specific treatment was instigated, according to the following protocol (figure 2): intravenous normal saline (na, 154 mmol/l; cl, 154 mmol/l; 500 ml × 2/day; daily), dexamethasone (8 mg per day × 2 consecutive days), nahco3 (80 mmol/l per day; daily), bortezomib (1.3 mg/m2 per dose, weekly), elcatonin (40 units per day for 5 consecutive days), and zoledronic acid hydrate (4 mg per dose, monthly). |
| PubMedID- 22073517 | multiple myeloma with hypercalcemia and chloride resistant metabolic alkalosis. |
| PubMedID- 26500541 | We now report what may well be the first clinical correlate of this laboratory finding in a patient who developed a hypokalemic metabolic alkalosis as a consequence of severe hypercalcemia due to multiple myeloma and whose metabolic derangement was corrected without the use of a loop diuretic which may have exacerbated the electrolyte abnormalities. |
| PubMedID- 24743202 | Bisphosphonates(bps)have been widely used for the treatment of hypercalcemia associated with cancer, multiple myeloma bone diseases, and bone metastasis of solid cancers. |
| PubMedID- 21915243 | Interestingly, aminobisphosphonates (abs) which are synthetic compounds commonly used to treat bone disease and hypercalcemia in patients with multiple myeloma, breast or prostate cancer, have been identified also as antigens for γδ t cells, indicating these molecules as immunomodulating factors –. |
| PubMedID- 25128013 | Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. |
Page: 1